Cross-tumoral Phase 2 With Crizotinib in Europe
Posted: Tue Oct 16, 2012 7:45 pm
If you are in Europe and have no any other options for treatment of the metastatic ASPS, you may consider enrolling into this trial:
Cross-tumoral Phase 2 With Crizotinib
http://clinicaltrials.gov/ct2/show/NCT01524926
Official Title: Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways including ASPS.
Ages Eligible for Study: 15 Years and older
Locations
Belgium
Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet Recruiting
Brussels, Belgium
U.Z. Gasthuisberg Recruiting
Leuven, Belgium
Cross-tumoral Phase 2 With Crizotinib
http://clinicaltrials.gov/ct2/show/NCT01524926
Official Title: Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways including ASPS.
Ages Eligible for Study: 15 Years and older
Locations
Belgium
Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet Recruiting
Brussels, Belgium
U.Z. Gasthuisberg Recruiting
Leuven, Belgium